Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hammad Amer

Vascular Surgery Mesa, AZ Medical Doctor

NPI 1154587459 CMS profile 52838

6636 E Baseline Rd Ste 100, Mesa, AZ 85206

Open in the dashboard

General payments

$168,580

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hammad Amer of Mesa, AZ is reported in the CMS Open Payments database as having received $168,580 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57,376 43
2024 General $62,353 37
2023 General $35,800 23
2022 General $1,549 24
2021 General $4,822 27
2020 General $2,628 35
2019 General $4,052 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hammad Amer
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Hammad Amer were reported at $57,376. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Hammad Amer Vascular Surgery median Middle half National median
2019 $4,052 $796 $226–$2,363 $163
2020 $2,628 $348 $118–$1,110 $114
2021 $4,822 $471 $158–$1,421 $132
2022 $1,549 $725 $222–$2,183 $149
2023 $35,800 $836 $257–$2,440 $160
2024 $62,353 $909 $252–$2,619 $164
2025 $57,376 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $156,136 26 payments
  2. W. L. Gore & Associates, Inc. $4,358 50 payments
  3. Endologix, Inc. $2,370 22 payments
  4. Medtronic Vascular, Inc. $1,605 23 payments
  5. Bolton Medical Inc $632 17 payments
  6. Bard Peripheral Vascular, Inc. $477 11 payments
  7. Medtronic, Inc. $454 16 payments
  8. Cook Medical LLC $395 13 payments
  9. Penumbra, Inc. $357 3 payments
  10. Abbott Laboratories $329 5 payments
  11. Other $1,467 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $149,583 6 payments
  2. Food and Beverage $9,566 219 payments
  3. Education $5,222 2 payments
  4. Consulting Fee $1,750 2 payments
  5. Travel and Lodging $1,459 8 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $98,861 5 payments
  2. Auryon Laser System 100-120 Vac Cv $54,750 2 payments
  3. Endurant $1,537 22 payments
  4. Product in Development $1,307 2 payments
  5. Auryon $1,194 1 payment
  6. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,090 11 payments
  7. AURYON LASER SYSTEM 100-120 VAC Pad $1,008 14 payments
  8. GORE TAG Thoracic Endoprosthesis $662 7 payments
  9. EXCLUDER Conformable AAA Endoprosthesis with Active Control $630 16 payments
  10. Alto Abdominal Stent Graft System $628 9 payments
  11. Other $7,570 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

384

Median for Vascular Surgery: 122

Drug cost

$118,125

Median for Vascular Surgery: $14,135

Branded share of claims

87.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 74 $80,845
Xarelto Rivaroxaban Brand 17 $28,795
Brilinta Ticagrelor Brand 12 $5,150
Clopidogrel Clopidogrel Bisulfate Brand 205 $2,423
Gabapentin Generic 36 $543
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $217
Cilostazol Generic 11 $153

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$319,294

Of which drugs: $110

Medicare patients

308

Average age 75

Services billed

2,365

158 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 53%
Chronic kidney disease 49%
Diabetes 45%
Atrial fibrillation 30%
Heart failure 28%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 29 1,077 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record